Steve Schonfeld’s AstraZeneca AZN Stock Holding History

Steve Schonfeld’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-225,000	Closed	-$485K	–	1775
2023 Q2	$485K	Buy	225,000 +75,000	+50%	+$11M	﹤0.01%	1234
2023 Q1	$1.05M	Buy	+150,000	New	+$20.2M	0.01%	938

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Steve Schonfeld's AZN Position: Q2 2026 in Review

Steve Schonfeld sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 42,071 shares — an estimated $8.3M sold.

Steve Schonfeld first reported a position in AZN in Q1 2016 and held it in 26 quarters. The position peaked at $66.6M in Q3 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Steve Schonfeld reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 42,071 AstraZeneca shares in Q2 2026, an estimated $8.3M.
Steve Schonfeld first reported a position in AstraZeneca in Q1 2016 and held it in 26 quarters.
Steve Schonfeld's AstraZeneca position peaked at $66.6M in Q3 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.